Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of @entity1 with @entity5 or XXXX .

@entity1 @entity242 @entity2301 @entity5 @entity3052 @entity1778
IGF binding proteins (IGFBP) regulate the bioavailability and bioactivity of IGF. The major IGFBP in serum is @entity2301 . We investigated whether sera from @entity1 with @entity5 show alterations in levels of @entity2301 as measured by Western ligand blot analysis (WLB) and RIA with alpha @entity2301 gl, a specific rabbit polyclonal antibody. Furthermore, @entity2301 proteolysis was quantified by densitometric analysis of [125I] @entity2301 protease assays, and @entity2301 fragments were visualized by Western immunoblot with alpha @entity2301 gl. We examined sera from 21 @entity1 with solid @entity5 , five @entity1 with @entity242 who had reached complete remission, and 13 @entity1 with @entity3052 . Serum samples were collected at diagnosis, before initiation of therapy. Sera of 10 healthy @entity1 served as normal controls. @entity1 with solid @entity5 or @entity1778 had significantly higher (p < 0.001) @entity2301 protease activity in serum than did normal controls or @entity1 with @entity242 in complete remission. Corresponding to this finding, densitometry of WLB showed lower @entity2301 levels in sera of @entity1 with @entity5 in comparison with normal controls. The negative correlation (p < 0.001, r = -0.80) between @entity2301 proteolysis, as measured by [125I] @entity2301 protease assay, and @entity2301 band density on WLB indicates that proteolysis is the probable reason for reduction of @entity2301 on WLB. @entity2301 concentrations measured by RIA were in the normal range for most @entity1 , further indicating that differences in serum @entity2301 levels measured by WLB reflect protease activity.(ABSTRACT TRUNCATED AT 250 WORDS)
